# IO102-IO103

Source: https://onco.cc/drugs/io102-io103/  
OnCo record `io102-io103` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IO102-IO103 is an experimental peptide (immunotherapeutic vaccine) from IO Biotech in phase 3 trials for melanoma and head and neck squamous cell carcinoma, aimed at PD-L1.

## Summary

IO102-IO103 (IO102, IO103) is a peptide (immunotherapeutic vaccine) developed by IO Biotech. Its target is PD-L1 (the sponsor names IDO1 and PD-L1). The sponsor states: IO102-IO103 comprises an IDO peptide antigen (IO102) and a PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) and given subcutaneously to stimulate an immune response against IDO- and PD-L1-expressing cells, dosed alongside pembrolizumab in advanced melanoma. ClinicalTrials.gov describes the intervention as: IO102-IO103 comprises IDO peptide antigen (IO102) and PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) administered subcutaneously. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05155254 (IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)), in melanoma and head and neck squamous cell carcinoma. The largest, NCT05155254, plans to enrol 407 participants (actual) with primary completion was scheduled for 2025-05-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: IO102, IO103
- Modality: peptide (immunotherapeutic vaccine)
- Mechanism: IO102-IO103 comprises an IDO peptide antigen (IO102) and a PD-L1 peptide antigen (IO103) emulsified with adjuvant (Montanide ISA 51 VG) and given subcutaneously to stimulate an immune response against IDO- and PD-L1-expressing cells, dosed alongside pembrolizumab in advanced melanoma.

## Sources

- ClinicalTrials.gov: trials of IO102-IO103: https://clinicaltrials.gov/search?intr=IO102

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/)
- targets: [IDO1](https://onco.cc/targets/ido1/), [PD-L1](https://onco.cc/targets/pdl1/)
- companies: [IO Biotech](https://onco.cc/companies/io-biotech/)
- trials: [IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)](https://onco.cc/trials/nct05155254/), [Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors](https://onco.cc/trials/nct05280314/)

---
JSON: https://onco.cc/api/v1/entities/io102-io103.json